Tesaro — Merger or Acquisition (March 2014)
20 slides from Tesaro's merger presentation, Mar 13, 2014
Slide 1: Immuno-Oncology Collaboration and License Agreement for TIM-3, LAG-3 and PD-1 Antibody Programs
Immuno-Oncology Collaboration and License Agreement for TIM-3, LAG-3 and PD-1 Antibody Programs March 13, 2014
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,
Slide 3: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 4: A Balanced Portfolio of Product Candidates
A/C: anthracycline/cyclophosphamide MEC: Moderately emetogenic chemotherapy; HEC: Highly emetogenic chemotherapy NSCLC: Non-small cell lung cancer * In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration A Balanced Portfolio of Product Candidates Compound Indication Disc
Slide 5: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 6: Financial Terms
Financial Terms Initiation payment: $17M (Q1 2014 R&D Expense) Funding of development costs for each program Potential milestone payments for each program: $18M for R&D-related achievements, including initiation of Phase 3 trials in an initial and a subsequent indication $90M for regulatory submissi
Slide 7: Mary Lynne Hedley, Ph.D., President
Mary Lynne Hedley, Ph.D. President
Slide 8: Strategic Rationale: TESARO's Vision for Immuno-Oncology
Immune modulators for oncology (IMOs) may replace chemotherapy as the treatment backbone in certain indications IMOs are likely to be utilized across many tumor types IMOs will be used as monotherapy and in combination Potential to combine IMOs with niraparib and TSR-011 Provides a competitive advan
Slide 9: Immuno-Oncology for the Treatment of Cancer
Immuno-oncology is based on the hypothesis that the immune system is the first defense against cancer Cancer is normally kept in check by immune surveillance Tumors evade this system by inducing a state of immune suppression Checkpoint receptors are co-opted by tumors to evade the immune system PD-1
Slide 10: Advantages of the AnaptysBio Approach
Advantages of the AnaptysBio Approach Mimicking the Natural Process for Eliciting an Antibody Response Under Controlled Conditions Generates Potent Human Antibodies Antibody Generation and Maturation via the Human Immune System Antibody Generation and Maturation via the SHM-XEL™ System
Slide 11: TSR-042: Anti-PD-1 Antibody Program
PD-1: checkpoint receptor that negatively regulates T cell function Expression is a hallmark of exhausted, dysfunctional T cells Binds PD-L1 and negates T cell activity Treatment with anti-PD-1 antibody restores T cell activity and leads to tumor regression in animal models Clinical studies demonstr
Slide 12: TSR-042 Anti-PD-1 Antibody
TSR-042 Anti-PD-1 Antibody* * Antibody produced based upon the disclosed sequence of BMS-936558. TSR-042 is a Potent Anti-PD-1 Antibody and Enhances Human T Cell Activity KinExA KD = 2 nM KinExA KD = 200 pM IL-2 (ng/ml) isotype TSR042 no mAb Potent Binding to PDL-1 Enhancement of Human T Cell IL-2 P
Slide 13: Anti-TIM-3 Antibody Program
IL-2 Production Activated CD4+ T cells at 48h Anti-TIM-3 Antibody Program Anti-TIM-3 Antibodies Enhance Tumor Regression in Combination with Anti-PD-1 Antibodies TIM-3: inhibitory receptor that negatively regulates T cell function Expression is a hallmark of exhausted, dysfunctional T cells Binds Ga
Slide 14: Anti-LAG-3 Antibody Program
LAG-3/MHC Class II Blockade Assay on Daudi Cells * Lymphocyte activation gene Anti-LAG-3 Antibody Program LAG-3: inhibitory receptor that negatively regulates T cell function Expressed on T and NK cells Binds MHC Class II and negates anti-tumor T cell activity Treatment with anti-LAG-3 antibody upre
Slide 15: Combination Blockade with anti-PD-1 and anti-TIM-3 Results in Tumor Regression
Sakuishi K et al. 2010 J Exp Med 207:2187. Combination Blockade with anti-PD-1 and anti-TIM-3 Antibodies Results in Tumor Regression Tumor size Day 20/21 Day 23/24 CT26 Colon Carcinoma Tumor Model Treatment: Anti-TIM-3 (5 mg/kg, d. 0, 2, 4) + Anti-PD-L1 (10 mg/kg, d. 0, 3, 6, 9, 12) rat IgG1, rat Ig
Slide 16: Combination Blockade with anti-PD-1 and anti-LAG-3 Results in Tumor Regression
Woo, SR, et al., 2012 Cancer Res. 72:917 Combination Blockade with anti-PD-1 and anti-LAG-3 Antibodies Results in Tumor Regression Anti-PD-1, 10 mg/kg Anti-LAG-3, 10 mg/kg Anti-LAG-3, 10 mg/kg + Anti-PD-1, 10 mg/kg Tumor volume (mm3/2) A/J mice + Sa1N fibrosarcoma C57BL/6 mice + MC-38 colon carcinom
Slide 17: Potential for Combination of ALK Inhibitors with Anti-PD-1 Antibody
Source: M. Marzec et. al, PNAS Potential for Combination of ALK Inhibitors with Anti-PD-1 Antibody ALK mutation induces expression of PD-L1 in T cell lymphomas Treatment with anti-PD-1 antibodies is most effective against tumors over-expressing PD-L1 FACS Analysis of Cell Lines for PD-L1 Expression
Slide 18: Advancing Our Oncology Strategy Summary
Immuno-oncology platform provides a portfolio of candidates focused on high value targets and augments the value of TESARO’s other pipeline candidates Enhances prospects for future collaborations Anticipated milestones: Potential first-in-class anti-TIM-3 antibody clinical candidate to be selected i
Slide 19: Q&A
Q&A W TESARO
Slide 20: Immuno-Oncology Collaboration and License Agreement for TIM-3, LAG-3 and PD-1 Antibody Programs
March 13, 2014 Immuno-Oncology Collaboration and License Agreement for TIM-3, LAG-3 and PD-1 Antibody Programs